Literature DB >> 12955407

Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery.

A Lochner1, S Genade, J A Moolman.   

Abstract

The search for the mechanism of preconditioning-induced cardioprotection has been hampered by controversial results obtained by workers using different animal species, experimental models, protocols and endpoints. The aim of this study was to evaluate the role of the perfusion model (retrograde vs working), the infarct size and severity of ischaemia (regional vs global) as well as the endpoint (functional recovery vs infarct size) in preconditioning. The isolated perfused rat heart was preconditioned by 3 x 5 min global ischaemia, followed by different periods of regional or global ischaemia and reperfusion. Ischaemic preconditioning of working hearts resulted in increased functional recovery after 25-35 min global ischaemia, while retrogradely perfused hearts showed no significant improvement (except after 30 min global ischaemia). In addition, the percentage reduction in functional performance during reperfusion observed in the latter group was significantly less than in working hearts. Hearts were also subjected to regional ischaemia, perfused in either retrograde or working mode and infarct size determined. Regionally ischaemic working as well as retrogradely perfused hearts when preconditioned showed a significant increase in functional recovery after 35 min ischaemia only. In contrast to global ischaemia, the percentage recovery in mechanical performance of regionally ischaemic hearts was not affected by the mode of perfusion. Preconditioning of working hearts caused a significant reduction in infarct size after both 30 and 35 min ischaemia. However, preconditioned retrogradely perfused hearts showed a significant decline in infarct size after 35 min regional ischaemia only. In conclusion, the effect of the perfusion mode on functional recovery is dependent on the size and severity of ischaemia. It also affects the ischaemic time at which infarct size reduction by prior preconditioning occurs in the retrogradely perfused heart.

Entities:  

Mesh:

Year:  2003        PMID: 12955407     DOI: 10.1007/s00395-003-0427-6

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  19 in total

Review 1.  Efficacy of preconditioning should be gauged by reduction of infarction.

Authors:  Michael V Cohen
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

Review 2.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

3.  Early cardiovascular changes occurring in diet-induced, obese insulin-resistant rats.

Authors:  Barbara Huisamen; Daneel Dietrich; Nicole Bezuidenhout; John Lopes; Brian Flepisi; Dee Blackhurst; Amanda Lochner
Journal:  Mol Cell Biochem       Date:  2012-05-26       Impact factor: 3.396

4.  ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance.

Authors:  B Huisamen; S J C Pêrel; S O Friedrich; R Salie; H Strijdom; A Lochner
Journal:  Mol Cell Biochem       Date:  2010-12-11       Impact factor: 3.396

5.  Preconditioning by subinotropic doses of ouabain in the Langendorff perfused rabbit heart.

Authors:  Eric E Morgan; Zhichuan Li; Cory Stebal; Aude Belliard; Glen Tennyson; Bijan Salari; Keith D Garlid; Sandrine V Pierre
Journal:  J Cardiovasc Pharmacol       Date:  2010-03       Impact factor: 3.105

6.  Landiolol does not enhance the effect of ischemic preconditioning in isolated rat hearts.

Authors:  Shuchun Yu; Takasumi Katoh; Hisako Okada; Hiroshi Makino; Soichiro Mimuro; Shigehito Sato
Journal:  J Anesth       Date:  2010-01-19       Impact factor: 2.078

7.  Polyphenol (-)-epigallocatechin gallate targeting myocardial reperfusion limits infarct size and improves cardiac function.

Authors:  Chan Jin Kim; Jin Mo Kim; Seung Ryong Lee; Young Ho Jang; June Hong Kim; Kook Jin Chun
Journal:  Korean J Anesthesiol       Date:  2010-02-28

8.  Effects of postconditioning with N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine in isolated rat hearts.

Authors:  Joon Hong Kim; Joon Kim; Yong-Hyeon Park; Kook Jin Cheun; Young-Ho Jang
Journal:  Korean J Anesthesiol       Date:  2010-03-29

9.  Polyphenol (-)-epigallocatechin gallate during ischemia limits infarct size via mitochondrial K(ATP) channel activation in isolated rat hearts.

Authors:  Dae-Kyu Song; Youngho Jang; June Hong Kim; Kook-Jin Chun; Deokhee Lee; Zhelong Xu
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

10.  Osteopontin protects against cardiac ischemia-reperfusion injury through late preconditioning.

Authors:  Yongyi Wang; Baofu Chen; Dafu Shen; Song Xue
Journal:  Heart Vessels       Date:  2009-04-01       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.